Comparative Pharmacology
Head-to-head clinical analysis: ETHACRYNIC ACID versus LASIX ONYU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHACRYNIC ACID versus LASIX ONYU.
ETHACRYNIC ACID vs LASIX ONYU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, potassium, and water. Also inhibits prostaglandin degradation.
Lasix (furosemide) inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption.
50 to 100 mg orally once daily; may increase by 25 to 50 mg increments at intervals of 2 to 3 days up to 400 mg/day. IV: 0.5 to 1 mg/kg slowly (over several minutes); usual initial dose 50 mg.
Furosemide 20-80 mg IV/PO once or twice daily; max 600 mg/day for IV, 80 mg/day for PO.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
1.5-2.0 hours in normal renal function; prolonged to 10-15 hours in severe renal impairment (CrCl <10 mL/min); clinically significant accumulation risk with repeated dosing in renal disease.
Primarily renal (approximately 60-70% as unchanged drug and metabolites) with some biliary/fecal excretion (approximately 30-40%).
Primarily renal (50-80% as unchanged drug); biliary/fecal (20-30%); non-renal clearance accounts for up to 20%.
Category C
Category C
Loop Diuretic
Loop Diuretic